📣 VC round data is live. Check it out!

LBX Pharmacy Valuation Multiples

Discover revenue and EBITDA valuation multiples for LBX Pharmacy and similar public comparables like Selçuk Ecza, Create SD Holdings, AiN Group, Anhui Huaren Health and more.

LBX Pharmacy Overview

About LBX Pharmacy

LBX Pharmacy Chain JSC is a China-based company engages in the sale of medicine and health products. The company is engaged in retailing drugs and other related products, including Chinese and Western medicine, prepared slices of Chinese crude drugs, health equipment, healthy food, and personal care products and life care products. The company is also involved in the wholesale and manufacture of drugs.


Founded

2005

HQ

China

Employees

N/A

Sectors

Financials (LTM)

Revenue: $3B
EBITDA: $320M

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

LBX Pharmacy Financials

LBX Pharmacy reported last 12-month revenue of $3B and EBITDA of $320M.

In the same LTM period, LBX Pharmacy generated $1B in gross profit, $320M in EBITDA, and $68M in net income.

Revenue (LTM)


LBX Pharmacy P&L

In the most recent fiscal year, LBX Pharmacy reported revenue of $3B and EBITDA of $341M.

LBX Pharmacy is profitable as of last fiscal year, with gross margin of 32%, EBITDA margin of 10%, and net margin of 2%.

See analyst estimates for LBX Pharmacy
LTMLast FY202320242025202620272028
Revenue$3B$3B$3B$3B$3B
Gross Profit$1B$1B$1B$1B$1B
Gross Margin33%32%33%33%32%
EBITDA$320M$341M$429M$376M$341M
EBITDA Margin10%10%13%11%10%
EBIT Margin4%5%7%5%5%
Net Profit$68M$56M$136M$76M$56M
Net Margin2%2%4%2%2%

Financial data powered by Morningstar, Inc.

LBX Pharmacy Stock Performance

LBX Pharmacy has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


LBX Pharmacy's stock price is $2.05.

LBX Pharmacy share price increased by 0.1% in the last 30 days, and decreased by 26.6% in the last year.

LBX Pharmacy has an EPS (earnings per share) of $0.07.

See more trading valuation data for LBX Pharmacy
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B0.0%0.1%-6.5%-26.6%$0.07

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

LBX Pharmacy Valuation Multiples

LBX Pharmacy trades at 0.5x EV/Revenue multiple, and 5.6x EV/EBITDA.

See NTM and 2027E valuation multiples for LBX Pharmacy

EV / Revenue (LTM)


LBX Pharmacy Financial Valuation Multiples

As of May 4, 2026, LBX Pharmacy has market cap of $2B and EV of $2B.

LBX Pharmacy has a P/E ratio of 23.0x.

LTMLast FY202320242025202620272028
EV/Revenue0.5x0.6x0.6x0.6x0.6x
EV/EBITDA5.6x5.3x4.2x4.8x5.3x
EV/EBIT13.4x10.8x8.0x10.2x10.8x
EV/Gross Profit1.6x1.7x1.7x1.7x1.7x
P/E23.0x27.8x11.4x20.5x27.8x
EV/FCF8.8x4.3x5.9x8.1x4.3x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified LBX Pharmacy Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

LBX Pharmacy Margins & Growth Rates

LBX Pharmacy grew revenue by 6% but EBITDA decreased by 1% in the last fiscal year.

In the most recent fiscal year, LBX Pharmacy reported gross margin of 32%, EBITDA margin of 10%, and net margin of 2%.

See estimated margins and future growth rates for LBX Pharmacy

LBX Pharmacy Margins

Last FY202420252026202720282029
Gross Margin32%33%32%33%
EBITDA Margin10%11%10%10%
EBIT Margin5%5%5%5%
Net Margin2%2%2%3%
FCF Margin13%7%13%4%

LBX Pharmacy Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth6%(0%)(1%)6%
Gross Profit Growth8%2%(3%)8%
EBITDA Growth(1%)(12%)(9%)(1%)
EBIT Growth3%(22%)(5%)3%
Net Profit Growth62%(44%)(26%)62%
FCF Growth(66%)(28%)90%(66%)

Data powered by FactSet, Inc. and Morningstar, Inc.

LBX Pharmacy Operational KPIs

LBX Pharmacy's Rule of 40 is 16% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

LBX Pharmacy's Rule of X is 26% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for LBX Pharmacy
LTMLast FY202320242025202620272028
Rule of 4017%16%
Bessemer Rule of X28%26%
S&M Expenses to Revenue21%21%8%8%8%
G&A Expenses to Revenue6%6%2%2%2%
R&D Expenses to Revenue0%0%0%0%0%
Opex to Revenue27%26%28%27%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

LBX Pharmacy Competitors

LBX Pharmacy competitors include Selçuk Ecza, Create SD Holdings, AiN Group, Anhui Huaren Health, Dis-Chem Pharmacies, Omnicell, Redcare Pharmacy, Medplus Health Services, Yixintang Pharmaceutical and Aldawaa Medical Services.

Most LBX Pharmacy public comparables operate across Pharmacies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Selçuk Ecza0.3x0.3x10.3x8.1x
Create SD Holdings0.4x0.4x6.4x
AiN Group0.7x0.5x9.7x6.5x
Anhui Huaren Health1.6x13.3x
Dis-Chem Pharmacies0.9x0.8x11.0x10.3x
Omnicell1.6x1.6x13.6x12.9x
Redcare Pharmacy0.4x0.4x20.9x17.8x
Medplus Health Services1.6x1.6x20.4x18.4x

This data is available for Pro users. Sign up to see all LBX Pharmacy competitors and their valuation data.

Start Free Trial

LBX Pharmacy Funding History

Before going public, LBX Pharmacy raised $557M in total equity funding, across 1 round.


LBX Pharmacy Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-19Secondary - publicFountainVest Partners; Primavera Capital Group$557MLaobaixing Pharmacy Chain (LBX) is a leading pharmaceutical retail chain in China, founded in 2001 in Hunan province. The company operates approximately 4,800 stores across 22 provinces, offering Chinese and Western medicines, health equipment, healthy food, and personal care items alongside wholesale and manufacturing operations. LBX was listed on the Shanghai Stock Exchange under stock code 603883. On 27 November 2019, FountainVest Partners and Primavera Capital Group jointly acquired a 24.78% stake in LBX from EQT Partners for USD 557 million. This represented the acquisition of Janstar Investment Limited and Zexing Investment, the second-largest shareholder at the time. The two investors split the 71 million shares evenly between their respective funds: FountainVest China Capital Partners Fund III and Primavera Capital Fund III. The transaction marked a significant strategic milestone for LBX, with both investors focused on leveraging their expertise in healthcare and new retail to drive accelerated development. Key strategic initiatives outlined included capitalizing on prescription drug outflows, embracing new retail models, expanding into rural markets, and increasing overall market share through technological innovation and digital transformation. As of 2024, LBX reported operating income of RMB 22,357.61 million, demonstrating the company's continued operations and market presence in China's pharmaceutical retail sector.

LBX Pharmacy M&A Activity

LBX Pharmacy has acquired 1 company to date.

Last acquisition by LBX Pharmacy was on December 11th 2021. LBX Pharmacy acquired Huairen Health for $324M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by LBX Pharmacy

Huairen Health
Description
Huairen Health is a pharmaceutical wholesaler and retailer under HNY Y Group, operating nationwide in China via hnyygroup.com. It distributes prescription drugs, medical supplies, and OTC products through a network of pharmacies and hospitals in Henan Province.
HQ CountryChina
HQ City
Huaihua
Deal Date11 Dec 2021
Valuation$324M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all LBX Pharmacy acquisitions and their M&A valuation multiples.

Start Free Trial

LBX Pharmacy Investment Activity

LBX Pharmacy has invested in 1 company to date.

Latest investment by LBX Pharmacy was on July 24th 2017. LBX Pharmacy invested in BAI JIA HUI SU HE PHARMACY in their $400K Angel round (EV/Revenue multiple of ).

See VC round multiples

Latest Investments by LBX Pharmacy

BAI JIA HUI SU HE PHARMACY
Description
BAI JIA HUI SU HE PHARMACY is a retail pharmacy chain operating in Jiangsu Province, China. The network provides prescription medications, over-the-counter drugs, health supplements, and medical devices through physical stores and online channels.
HQ CountryChina
HQ City
Suzhou
Deal Date24 Jul 2017
RoundAngel
Raised$400K
InvestorsLBX Pharmacy
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all LBX Pharmacy investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About LBX Pharmacy

When was LBX Pharmacy founded?LBX Pharmacy was founded in 2005.
Where is LBX Pharmacy headquartered?LBX Pharmacy is headquartered in China.
Is LBX Pharmacy publicly listed?Yes, LBX Pharmacy is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of LBX Pharmacy?LBX Pharmacy trades under 603883 ticker.
When did LBX Pharmacy go public?LBX Pharmacy went public in 2015.
Who are competitors of LBX Pharmacy?LBX Pharmacy main competitors include Selçuk Ecza, Create SD Holdings, AiN Group, Anhui Huaren Health, Dis-Chem Pharmacies, Omnicell, Redcare Pharmacy, Medplus Health Services, Yixintang Pharmaceutical, Aldawaa Medical Services.
What is the current market cap of LBX Pharmacy?LBX Pharmacy's current market cap is $2B.
What is the current revenue of LBX Pharmacy?LBX Pharmacy's last 12 months revenue is $3B.
What is the current revenue growth of LBX Pharmacy?LBX Pharmacy revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of LBX Pharmacy?Current revenue multiple of LBX Pharmacy is 0.5x.
Is LBX Pharmacy profitable?Yes, LBX Pharmacy is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of LBX Pharmacy?LBX Pharmacy's last 12 months EBITDA is $320M.
What is LBX Pharmacy's EBITDA margin?LBX Pharmacy's last 12 months EBITDA margin is 10%.
What is the current EV/EBITDA multiple of LBX Pharmacy?Current EBITDA multiple of LBX Pharmacy is 5.6x.
What is the current FCF of LBX Pharmacy?LBX Pharmacy's last 12 months FCF is $204M.
What is LBX Pharmacy's FCF margin?LBX Pharmacy's last 12 months FCF margin is 6%.
What is the current EV/FCF multiple of LBX Pharmacy?Current FCF multiple of LBX Pharmacy is 8.8x.
How many companies LBX Pharmacy has acquired to date?As of May 2026, LBX Pharmacy has acquired 1 company.
What was the largest acquisition by LBX Pharmacy?$324M acquisition of Huairen Health on 11th December 2021 was the largest M&A LBX Pharmacy has done to date.
What companies LBX Pharmacy acquired?LBX Pharmacy acquired Huairen Health.
In how many companies LBX Pharmacy has invested to date?As of May 2026, LBX Pharmacy has invested in 1 company.
What was the last LBX Pharmacy investment?On 24th July 2017 LBX Pharmacy invested in BAI JIA HUI SU HE PHARMACY, participating in a $400K Angel round.
In what companies LBX Pharmacy invested in?LBX Pharmacy invested in BAI JIA HUI SU HE PHARMACY.

See public comps similar to LBX Pharmacy

Lists including LBX Pharmacy

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial